Suppliers and packagers for FORTEO

FORTEO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA	Eli Lilly and Company	0002-8400-01	1 SYRINGE in 1 CARTON (0002-8400-01) / 2.24 mL in 1 SYRINGE	2002-11-26
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA	Eli Lilly and Company	0002-9678-01	1 SYRINGE in 1 CARTON (0002-9678-01) / 2.24 mL in 1 SYRINGE	2025-06-03
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-495-28	1 SYRINGE in 1 CARTON (66993-495-28) / 2.24 mL in 1 SYRINGE	2023-11-17
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-989-28	1 SYRINGE in 1 CARTON (66993-989-28) / 2.24 mL in 1 SYRINGE	2025-06-16

Suppliers for Forteo (teriparatide): What companies manufacture, fill-finish, and supply key components

Last updated: May 27, 2026

Forteo is a branded teriparatide (recombinant human parathyroid hormone 1-34) injection. The supplier base for Forteo is primarily defined by (1) the upstream biologics manufacturing of the active pharmaceutical ingredient (API) and (2) the downstream drug product fill-finish and packaging suppliers listed on regulatory filings and product labeling. Supplier names vary by jurisdiction and manufacturing site, and the practical “supplier set” for a partner depends on whether the work is for the API, the drug product, or secondary packaging.

Which companies supply Forteo’s drug product fill-finish and packaging?

Forteo is supplied as a pen injector containing teriparatide solution. The pen device and its labeling, plus the drug product container closure system (cartridge/pen components) and external packaging, are typically sourced from device and packaging vendors integrated into the manufacturer’s global supply chain. In the U.S., the “supplier” set that matters for regulatory and change-control planning is the set of manufacturing sites controlled by the product holder and listed on the drug label and FDA submission documents.

What does Forteo’s U.S. label reveal about manufacturing sites?

In practice, the fastest compliance path for identifying true “supplier” responsibility is mapping the FDA-labeled manufacturing site(s) for:

• Drug product manufacturing (fill-finish, sterile filling, assembly of the pen/cartridge components controlled under the manufacturing license)
• Packaging operations (sterile product kit assembly and cartoning where applicable)
• Distribution and labeling responsibilities (often by the product holder’s affiliates)

How to interpret “suppliers” for Forteo in contract manufacturing terms

For teriparatide pens, “suppliers” usually split into:

• API supplier (biotech upstream or recombinant peptide manufacturing)
• Fill-finish supplier (sterile manufacturing under aseptic processing controls)
• Pen/cartridge supplier (device component supplier or integrated device manufacturer through the primary manufacturer)
• Secondary packaging supplier (cartoning, labeling, inserts)

Because pen injectors involve regulated device components, vendor changes can trigger bridging studies or additional quality submissions depending on what changes and which critical quality attributes are affected.

What patents and regulatory filings identify Forteo manufacturing and supply chain responsibility?

The supplier network for a branded biologic like teriparatide is not usually disclosed in patent texts line-by-line. However, manufacturing sites and process responsibility are frequently tied to:

• FDA Chemistry, Manufacturing, and Controls (CMC) sections
• FDA-approved manufacturing location lists
• Platform manufacturing process descriptions in NDAs and supplements
• Device-related assembly/packaging descriptions in label sections

For supplier identification used in due diligence, the reliable artifacts are FDA-labeled manufacturing sites for the drug product and the pen presentation controlled by the product holder’s CMC package.

What entity controls Forteo’s manufacturing process in the U.S.?

Forteo is marketed in the U.S. by Eli Lilly and Company (and historically through Lilly’s affiliates for distribution). Manufacturing and fill-finish are executed through Lilly’s internal or contracted manufacturing network, with the specific responsible sites identified on the product labeling and CMC filings.

What is the practical “supplier answer” for diligence?

For licensing, litigation, and sourcing decisions, “suppliers” should be treated as:

• Named manufacturing sites that produce and fill-finish Forteo (site-level responsibility)
• Listed device/kit components incorporated into the pen/cartridge (component-level responsibility)
• The API manufacturing program controlled under the teriparatide CMC system (lot-level responsibility)

Those are the entities that drive:

• batch release and sterility testing ownership
• quality agreements with downstream partners
• change-control notifications for manufacturing supplements

How do biosimilar or generic competitors impact the Forteo supplier ecosystem?

Forteo is a biologic drug (recombinant peptide). That limits “generic” pathways and typically shifts competitive pressure to:

• biosimilar or follow-on biologics development (where applicable)
• lifecycle management through formulation and device updates (within the brand)

Supplier ecosystems for competitors often differ, with separate upstream and fill-finish vendors. For supplier planning, the relevant question becomes: can a competitor secure comparable API and aseptic fill-finish capacity without compromising sterility and potency controls?

Does biosimilar entry change Forteo supplier risk?

It can change commercial supplier leverage, but it does not usually change Lilly’s contracted manufacturing network for existing supply. The supply risk for Forteo depends more on:

• single-site or constrained-site fill-finish
• pen/cartridge component sourcing
• sterility assurance capacity and inspection history

When does Forteo lose exclusivity and what does that do to supply strategy?

Forteo’s exclusivity timing depends on the combination of patent estate and regulatory exclusivity (data exclusivity and any patent-term adjustments). The key sourcing implication is that when exclusivity narrows, downstream buyers (wholesalers, hospitals, payers) can push for lower-cost sourcing and manufacturing redundancy. That drives:

• dual sourcing of device components (pen/cartridge)
• additional fill-finish capacity
• more qualified suppliers for sterile filling consumables

What is the supplier implication of patent expirations?

When biosimilar/follow-on market pressure rises, product holders typically protect supply continuity by:

• qualifying alternate pen/cartridge suppliers
• qualifying additional fill-finish lines or sites under existing CMC controls
• locking supply agreements for key sterile filling consumables

What packaging and device suppliers matter for Forteo pens?

The pen injector has regulated device components and assembly steps. The supplier set that matters operationally includes:

• cartridge/pen container closure components
• sterile connector and assembly consumables
• pen housing and actuation components
• labeling and patient insert printers and carton suppliers integrated into GMP-controlled packaging

Because device component sourcing is tightly controlled, most changes flow through controlled change-control systems and often require manufacturing supplements and comparability data.

Competitive landscape: whose supply chains can match teriparatide pen delivery?

A credible competitive picture for teriparatide must include:

• upstream API manufacturing capability for recombinant human PTH(1-34)
• aseptic sterile fill-finish capacity with peptide stability controls
• pen device supply and assembly capability

Competitors tend to build supplier chains with:

• at least two manufacturing sites (API and fill-finish) or a backup line strategy
• contracted sterile filling houses qualified for biologic peptides
• an integrated device component supplier strategy to reduce launch risk

Table: Forteo supplier categories and diligence targets (site-level vs component-level)

Supplier category	What you need to name for diligence	Typical risk if wrong	Key diligence artifacts
API manufacturer	The API manufacturing site/program responsible for teriparatide lots	Potency, impurity profile drift; regulatory comparability failures	CMC site lists; batch release testing scope
Sterile fill-finish manufacturer	The site responsible for aseptic filling and primary container closure operations	Sterility assurance failures; batch rejections	FDA manufacturing location references; inspection history
Pen/cartridge assembly	The controlled device component assembly within GMP	Device part variation affecting dose delivery	Device/kit component specs; comparability protocols
Packaging and labeling	The cartons, labels, and inserts integrated into finished-goods labeling	Labeling mix-ups; distribution noncompliance	Lot-level packaging records; labeling QA
Secondary suppliers	Sterile consumables and critical materials	Lead-time shocks; lot-to-lot variability	Quality agreements; incoming QC/testing

Key takeaways

• For Forteo, the practical supplier map for business decisions is site-level: API manufacturing program, sterile fill-finish, and pen/cartridge assembly operations under GMP.
• Packaging and pen device components are not “generic” commodity buys; supplier changes require controlled quality, comparability, and regulatory processes.
• Supplier continuity risk is concentrated in aseptic fill-finish capacity and pen/cartridge component sourcing rather than only API supply.

FAQs

1) Who manufactures teriparatide (Forteo) active ingredient for the U.S. product?
Forteo API is produced under Lilly-controlled manufacturing programs; the responsible entity for commercial lots is identified by the drug product and CMC manufacturing site listings tied to the NDA.

2) Are there different suppliers for Forteo pen injectors vs traditional vials?
Yes. Forteo’s pen presentation requires pen/cartridge component suppliers and GMP-controlled pen assembly that differ from any non-pen presentations.

3) What supplier changes trigger regulatory supplements for Forteo?
Changes to sterile fill-finish sites, pen/cartridge materials or suppliers affecting critical quality attributes, and other CMC-impacting process changes typically trigger regulatory review through comparability/CMC supplements.

4) Can third-party manufacturers supply Forteo pens under contract?
In principle, pen assembly and sterile fill-finish can be contracted, but the controlling responsibility and approved manufacturing sites remain tied to Lilly’s regulatory filings and quality system.

5) How do biosimilar launches affect Forteo sourcing and supplier leverage?
They increase commercial pressure to ensure supply resilience and cost competitiveness, usually resulting in dual sourcing of key inputs and additional qualified manufacturing capacity over time.

References (APA)

1. Eli Lilly and Company. (n.d.). Forteo (teriparatide) prescribing information. U.S. Food and Drug Administration, Labeling.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Forteo (teriparatide) [Product information].